Neximmune Financials

Neximmune Stock Summary

Neximmune competes with ZyVersa Therapeutics, Palisade Bio, Unicycive Therapeutics, Immix Biopharma, and Transcode Therapeutics. NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.

Neximmune Key Financial Ratios

Neximmune's financial ratios allow both analysts and investors to convert raw data from Neximmune's financial statements into concise, actionable information that can be used to evaluate the performance of Neximmune over time and compare it to other companies across industries.

Neximmune Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Neximmune's current stock value. Our valuation model uses many indicators to compare Neximmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neximmune competition to find correlations between indicators driving Neximmune's intrinsic value. More Info.Neximmune is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neximmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neximmune's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Neximmune Market Pulse

Along with financial statement analysis, the daily predictive indicators of Neximmune help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neximmune. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neximmune based on widely used predictive technical indicators. In general, we focus on analyzing Neximmune Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neximmune's daily price indicators and compare them against related drivers.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.